tetano
Editor, Senior Moderator
Arch Immunol Ther Exp (Warsz)
. 2023 Feb 28;71(1):8.
doi: 10.1007/s00005-023-00672-1.
The Effects of Statins on Respiratory Symptoms and Pulmonary Fibrosis in COVID-19 Patients with Diabetes Mellitus: A Longitudinal Multicenter Study
Mohammadamin Sadeghdoust[SUP] 1 [/SUP], Farnaz Aligolighasemabadi[SUP] 1 [/SUP], Tania Dehesh[SUP] 2 [/SUP], Nima Taefehshokr[SUP] 3 [/SUP], Adel Sadeghdoust[SUP] 4 [/SUP], Katarzyna Kotfis[SUP] 5 [/SUP], Amirhossein Hashemiattar[SUP] 6 [/SUP], Amir Ravandi[SUP] 7 [/SUP], Neda Aligolighasemabadi[SUP] 8 [/SUP], Omid Vakili[SUP] 9 [/SUP], Beniamin Grabarek[SUP] 10 11 12 [/SUP], Rafał Staszkiewicz[SUP] 10 13 [/SUP], Marek J Łos[SUP] 14 15 [/SUP], Pooneh Mokarram[SUP] 16 [/SUP], Saeid Ghavami[SUP] 17 18 19 20 21 [/SUP]
Affiliations
Abstract
The aim of this prospective cohort study was to explore the effect of statins on long-term respiratory symptoms and pulmonary fibrosis in coronavirus disease 2019 (COVID-19) patients with diabetes mellitus (DM). Patients were recruited from three tertiary hospitals, categorized into Statin or Non-statin groups, and assessed on days 0, 28, and 90 after symptoms onset to record the duration of symptoms. Pulmonary fibrosis was scored at baseline and follow-up time points by high-resolution computed tomography scans. Each group comprised 176 patients after propensity score matching. Data analysis revealed that the odds of having cough and dyspnea were significantly higher in the Non-statin group compared to the Statin group during the follow-up period. Overall, there was no significant difference in the change in pulmonary fibrosis score between groups. However, Non-statin patients with > 5 years of DM were more likely to exhibit a significantly higher fibrosis score during the follow-up period as compared to their peers in the Statin group. Our results suggest that the use of statins is associated with a lower risk of developing chronic cough and dyspnea in diabetic patients with COVID-19, and may reduce pulmonary fibrosis associated with COVID-19 in patients with long-term (> 5 years) DM.
Keywords: COVID-19; Diabetes mellitus; Post-acute COVID-19 syndrome; Pulmonary fibrosis; Statins.
. 2023 Feb 28;71(1):8.
doi: 10.1007/s00005-023-00672-1.
The Effects of Statins on Respiratory Symptoms and Pulmonary Fibrosis in COVID-19 Patients with Diabetes Mellitus: A Longitudinal Multicenter Study
Mohammadamin Sadeghdoust[SUP] 1 [/SUP], Farnaz Aligolighasemabadi[SUP] 1 [/SUP], Tania Dehesh[SUP] 2 [/SUP], Nima Taefehshokr[SUP] 3 [/SUP], Adel Sadeghdoust[SUP] 4 [/SUP], Katarzyna Kotfis[SUP] 5 [/SUP], Amirhossein Hashemiattar[SUP] 6 [/SUP], Amir Ravandi[SUP] 7 [/SUP], Neda Aligolighasemabadi[SUP] 8 [/SUP], Omid Vakili[SUP] 9 [/SUP], Beniamin Grabarek[SUP] 10 11 12 [/SUP], Rafał Staszkiewicz[SUP] 10 13 [/SUP], Marek J Łos[SUP] 14 15 [/SUP], Pooneh Mokarram[SUP] 16 [/SUP], Saeid Ghavami[SUP] 17 18 19 20 21 [/SUP]
Affiliations
- PMID: 36853269
- DOI: 10.1007/s00005-023-00672-1
Abstract
The aim of this prospective cohort study was to explore the effect of statins on long-term respiratory symptoms and pulmonary fibrosis in coronavirus disease 2019 (COVID-19) patients with diabetes mellitus (DM). Patients were recruited from three tertiary hospitals, categorized into Statin or Non-statin groups, and assessed on days 0, 28, and 90 after symptoms onset to record the duration of symptoms. Pulmonary fibrosis was scored at baseline and follow-up time points by high-resolution computed tomography scans. Each group comprised 176 patients after propensity score matching. Data analysis revealed that the odds of having cough and dyspnea were significantly higher in the Non-statin group compared to the Statin group during the follow-up period. Overall, there was no significant difference in the change in pulmonary fibrosis score between groups. However, Non-statin patients with > 5 years of DM were more likely to exhibit a significantly higher fibrosis score during the follow-up period as compared to their peers in the Statin group. Our results suggest that the use of statins is associated with a lower risk of developing chronic cough and dyspnea in diabetic patients with COVID-19, and may reduce pulmonary fibrosis associated with COVID-19 in patients with long-term (> 5 years) DM.
Keywords: COVID-19; Diabetes mellitus; Post-acute COVID-19 syndrome; Pulmonary fibrosis; Statins.